Fig. 2

Neuroimaging measure changes from baseline through 24 weeks in composite region of interest. A-B PET was performed to detect SV2A at baseline, 12 and 24 weeks (A) and to detect FDG at baseline and 24 weeks (B). No statistical differences were observed between treatment groups in change from baseline for either SV2A or FDG. Actual change relative to the cerebellum reference region is shown; error bars represent SE values. C Subjects were assessed using MRI at baseline, 12, and 24 weeks. The mean change from baseline in volumetric MRI (mL) (error bars: SE) for the composite of brain regions showed a trend towards less volume loss for the combined dose groups vs. placebo